|
EC 2.1.1.348 (mRNA m6A methyltransferase) inhibitor
|
CHEBI_172326 |
|
|
EC 3.2.1.52 (beta-N-acetylhexosaminidase) inhibitor
|
CHEBI_184301 |
|
|
EC 2.7.3.2 (creatine kinase) inhibitor
|
CHEBI_73354 |
|
|
EC 2.7.3.* (phosphotransferases with a nitrogenous group as acceptor) inhibitor
|
CHEBI_76818 |
|
|
protein-sequencing agent
|
CHEBI_73352 |
|
|
sclerotherapy agent
|
CHEBI_63923 |
|
|
negative regulation of membrane potential
|
GO_0045837 |
|
|
erythromelalgia
|
DOID_9240 |
|
|
neuropathy
|
DOID_870 |
|
|
positive regulation of membrane potential
|
GO_0045838 |
|
|
EC 4.2.1.1 (carbonic anhydrase) inhibitor
|
CHEBI_23018 |
|
|
mitotic M phase
|
GO_0000087 |
|
|
mitotic G2 phase
|
GO_0000085 |
|
|
G2 phase
|
GO_0051319 |
|
|
mitotic S phase
|
GO_0000084 |
|
|
S phase
|
GO_0051320 |
|
|
mitotic G1 phase
|
GO_0000080 |
|
|
G1 phase
|
GO_0051318 |
|
|
mass spectrometer degradation product
|
CHEBI_232530 |
|
|
methionine aminopeptidase 2 inhibitor
|
CHEBI_73361 |
|
